# Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

> **NCT00030784** · PHASE1 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 28 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** ifosfamide
- **DRUG:** pegylated liposomal doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00030784
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2005-03
- **Final completion:** —
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2012-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00030784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00030784, "Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00030784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*